{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:52:12Z","timestamp":1792651932906,"version":"4.5.0"},"reference-count":30,"publisher":"Society of Nuclear Medicine","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.2967\/jnumed.118.210443","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T12:26:14Z","timestamp":1523017574000},"page":"1415-1422","source":"Crossref","is-referenced-by-count":896,"title":["Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein"],"prefix":"10.2967","volume":"59","author":[{"given":"Thomas","family":"Lindner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Loktev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Altmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederik","family":"Giesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Kratochwil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Debus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Mier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Haberkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"2021051712122522000_59.9.1415.1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.279737.116"},{"key":"2021051712122522000_59.9.1415.2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.51.36505"},{"key":"2021051712122522000_59.9.1415.3","first-page":"3327","article-title":"Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin","volume":"53","author":"Rettig","year":"1993","journal-title":"Cancer Res."},{"key":"2021051712122522000_59.9.1415.4","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.18.7235"},{"key":"2021051712122522000_59.9.1415.5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1746"},{"key":"2021051712122522000_59.9.1415.6","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e31816618ce"},{"key":"2021051712122522000_59.9.1415.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.01.011"},{"key":"2021051712122522000_59.9.1415.8","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP86PPBNGOHNNL"},{"key":"2021051712122522000_59.9.1415.9","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023055600919"},{"key":"2021051712122522000_59.9.1415.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-4658.2011.08051.x"},{"key":"2021051712122522000_59.9.1415.11","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3184"},{"key":"2021051712122522000_59.9.1415.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2005.03.002"},{"key":"2021051712122522000_59.9.1415.13","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.274.35.24947"},{"key":"2021051712122522000_59.9.1415.14","doi-asserted-by":"publisher","DOI":"10.1172\/JCI26532"},{"key":"2021051712122522000_59.9.1415.15","doi-asserted-by":"publisher","DOI":"10.1126\/science.1195300"},{"key":"2021051712122522000_59.9.1415.16","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.1994.12.6.1193","article-title":"Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts","volume":"12","author":"Welt","year":"1994","journal-title":"J Clin Oncol."},{"key":"2021051712122522000_59.9.1415.17","first-page":"1639","article-title":"A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer","volume":"9","author":"Scott","year":"2003","journal-title":"Clin Cancer Res."},{"key":"2021051712122522000_59.9.1415.18","doi-asserted-by":"publisher","DOI":"10.1159\/000069863"},{"key":"2021051712122522000_59.9.1415.19","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0027"},{"key":"2021051712122522000_59.9.1415.20","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-3041"},{"key":"2021051712122522000_59.9.1415.21","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5211"},{"key":"2021051712122522000_59.9.1415.22","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs336"},{"key":"2021051712122522000_59.9.1415.23","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-1170"},{"key":"2021051712122522000_59.9.1415.24","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2805"},{"key":"2021051712122522000_59.9.1415.25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.advms.2015.04.006","article-title":"Specific inhibition of fibroblast activation protein (FAP)-alpha prevents tumor progression in vitro","volume":"60","author":"Teichgr\u00e4ber","year":"2015","journal-title":"Adv Med Sci."},{"key":"2021051712122522000_59.9.1415.26","doi-asserted-by":"crossref","unstructured":"Loktev A Lindner T Mier W . A new method for tumor imaging by targeting cancer associated fibroblasts. J Nucl Med. April 6, 2018 [Epub ahead of print].","DOI":"10.2967\/jnumed.118.210435"},{"key":"2021051712122522000_59.9.1415.27","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0644"},{"key":"2021051712122522000_59.9.1415.28","doi-asserted-by":"publisher","DOI":"10.1021\/jm500031w"},{"key":"2021051712122522000_59.9.1415.29","doi-asserted-by":"publisher","DOI":"10.1021\/tx200211v"},{"key":"2021051712122522000_59.9.1415.30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1023\/A:1008741731244","article-title":"The influence of lipophilicity on the pharmacokinetic behavior of drugs: concepts and examples","volume":"19","author":"Testa","year":"2000","journal-title":"Perspect Drug Discov Des."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.118.210443","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T05:36:10Z","timestamp":1660800970000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.118.210443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":30,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2018,9,4]]},"published-print":{"date-parts":[[2018,9]]}},"alternative-id":["10.2967\/jnumed.118.210443"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.118.210443","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,6]]}}}